Evidence map›Paper›PMID 40546970›Full record

ArticleClinical Medicine Insights. Oncology2025

Aysegul Gonc, Ozge Sukruoglu Erdogan, Seda Kilic Erciyas, Betul Celik Demirbas, Ahmet Dinc, Ozge Pasin, Pınar Saip, Hulya Yazici, Seref Bugra Tuncer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aysegul GoncInstitute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Türkiye.
Ozge Sukruoglu ErdoganDepartment of Cancer Genetics, Oncology Institute, Istanbul University, Istanbul, Türkiye.
Seda Kilic ErciyasDepartment of Cancer Genetics, Oncology Institute, Istanbul University, Istanbul, Türkiye.
Betul Celik DemirbasDepartment of Cancer Genetics, Oncology Institute, Istanbul University, Istanbul, Türkiye.
Ahmet DincInstitute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Türkiye.ORCID https://orcid.org/0000-0002-5985-070X
Ozge PasinDepartment of Biostatistics and Medical Informatics, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul, Türkiye.
Pınar SaipDepartment of Medical Oncology, Oncology Institute, Istanbul University, Istanbul, Türkiye.
Hulya YaziciMedical Biology and Genetics Department, Medical Faculty, Istanbul Health and Technology University, Istanbul, Türkiye.
Seref Bugra TuncerDepartment of Cancer Genetics, Oncology Institute, Istanbul University, Istanbul, Türkiye.ORCID https://orcid.org/0000-0001-8023-3223

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ovarian cancer (OC) is a significant health problem often diagnosed at an advanced stage due to the lack of early symptoms and effective screening methods. This study aimed to explore the role of Methods: DNA isolation was performed in the blood samples of 387 ovarian cancer patients, 50 individuals with benign ovarian diseases, and 100 healthy controls. The Results: Ovarian cancer patients exhibited the highest mean methylation percentage (9.45%) and median (6.23%), followed by healthy controls with a mean of 9.14% and a median value of 4.47%. Statistical analysis showed significant differences in methylation levels ( Conclusion: The

Indexed as

biomarkerCYB5R4 geneDNA methylationearly detectionOvarian cancer

Identifiers

PMID40546970
PMCPMC12181711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.